交易 Capricor Therapeutics Inc - CAPR CFD

Capricor Therapeutics, Inc., a biotechnology company, focuses on the development of transformative cell- and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases. The company''s lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase II clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with COVID-19; and completed various trials investigating the use of CAP-1002 for the treatment of cardiac conditions, including heart failure and post myocardial infarction with cardiac dysfunction. It is also developing CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in preclinical stage for the potential prevention of COVID-19. Capricor collaborates with Lonza Houston, Inc. for the development of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in Beverly Hills, California.

最新股票文章

日圓走勢預測
日圓走勢預測:第三方價格目標
2025年截至目前,美元兌日圓(USD/JPY)匯率年內下跌約9.41%。2025年4月25日,日圓兌美元收於142.8790,創下自2024年9月以來的最強水平之一,較2024年7月的高點161.942下跌約11.77%。
11:17, 19 6月 2025
寧德時代(CATL)股票預測
寧德時代(CATL)股票預測:第三方價格目標
探索寧德時代(CATL)2025年及未來的股價預測,涵蓋分析師目標價等關鍵訊息
13:25, 11 6月 2025
2025-2030年油價走勢預測:第三方價格目標
探索2025年及以後的第三方石油價格預測,涵蓋分析師目標、歷史價格和交易策略。
16:57, 2 6月 2025
2025年黃金價格預測:第三方目標
黃金價格走勢分析2025:第三方目標與市場預測
黃金一直被視為經濟不確定時期的重要避險資產。隨著2025年受中央銀行政策轉向、通脹壓力變化以及地緣政治緊張局勢的影響,黃金在交易圈中仍然備受關注。
21:45, 28 4月 2025